Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Down 9.6% in July

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 58,600 shares, a decline of 9.6% from the July 15th total of 64,800 shares. Approximately 6.0% of the shares of the stock are sold short. Based on an average daily volume of 19,800 shares, the short-interest ratio is presently 3.0 days.

Institutional Trading of Avalo Therapeutics

A hedge fund recently bought a new stake in Avalo Therapeutics stock. Affinity Asset Advisors LLC acquired a new stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $218,000. Affinity Asset Advisors LLC owned approximately 0.97% of Avalo Therapeutics as of its most recent SEC filing. 87.06% of the stock is owned by hedge funds and other institutional investors.

Avalo Therapeutics Stock Down 2.5 %

NASDAQ AVTX traded down $0.23 during mid-day trading on Friday, reaching $9.07. 10,815 shares of the stock were exchanged, compared to its average volume of 286,616. The business’s fifty day simple moving average is $11.70 and its 200 day simple moving average is $10.34. Avalo Therapeutics has a 1-year low of $3.95 and a 1-year high of $71.04.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($14.07) EPS for the quarter, missing analysts’ consensus estimates of ($6.70) by ($7.37). Avalo Therapeutics had a negative net margin of 1,639.50% and a negative return on equity of 1,439.87%. As a group, sell-side analysts anticipate that Avalo Therapeutics will post -28.11 earnings per share for the current year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.